152 related articles for article (PubMed ID: 30335894)
1. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract][Full Text] [Related]
2. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
3. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
Gao Y; Liu X; Li T; Wei L; Yang A; Lu Y; Zhang J; Li L; Wang S; Yin F
Oncol Rep; 2017 May; 37(5):3084-3092. PubMed ID: 28350120
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
5. Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer
Ke Y; Chen X; Su Y; Chen C; Lei S; Xia L; Wei D; Zhang H; Dong C; Liu X; Yin F
Front Oncol; 2021; 11():744940. PubMed ID: 34790572
[TBL] [Abstract][Full Text] [Related]
6. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
[No Abstract] [Full Text] [Related]
7. Low expression of KCNN3 may affect drug resistance in ovarian cancer.
Liu X; Wei L; Zhao B; Cai X; Dong C; Yin F
Mol Med Rep; 2018 Aug; 18(2):1377-1386. PubMed ID: 29901154
[TBL] [Abstract][Full Text] [Related]
8. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
[TBL] [Abstract][Full Text] [Related]
10. Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer.
Yan B; Xiong C; Huang F; Zhang M; Mo Y; Bai H
Medicine (Baltimore); 2020 Jul; 99(27):e20802. PubMed ID: 32629664
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.
Zheng R; Chen W; Xia W; Zheng J; Zhou Q
Biomed Res Int; 2020; 2020():7658782. PubMed ID: 33282953
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
15. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
[TBL] [Abstract][Full Text] [Related]
16. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
Martín de la Fuente L; Malander S; Hartman L; Jönsson JM; Ebbesson A; Nilbert M; Måsbäck A; Hedenfalk I
Int J Gynecol Pathol; 2018 Mar; 37(2):101-109. PubMed ID: 28481779
[TBL] [Abstract][Full Text] [Related]
17. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
19. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
20. Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer.
Feng Y; Hang W; Sang Z; Li S; Xu W; Miao Y; Xi X; Huang Q
Mol Med Rep; 2019 May; 19(5):3376-3392. PubMed ID: 30864705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
